<p>GRAIL, Inc.（纳斯达克代码：GRAL - 获取免费报告）周一股价下跌 4%，原因是公司内部人士出售了该公司的股票。该公司股价最低曾达到 60.02 美元，最后交易价格为 62.95 美元。在交易过程中，约有 494,947 股成交，较日均成交量 1,277,161 股下降了 61%。该股票此前收盘价为 65.55 美元。</p>
<ul>
<li>2025 年表现优于市场的 3 只医疗科技股票</li>
</ul>
<p>具体来说，首席执行官 Joshua J. Ofman 在 10 月 2 日星期四出售了 9,692 股公司的股票。股票的平均售价为 64.00 美元，总价值为 620,288.00 美元。交易后，首席执行官直接持有 478,182 股公司股票，价值 30,603,648 美元。这笔交易使其持股比例减少了 1.99%。该交易已在提交给证券交易委员会的文件中披露，相关文件可通过此链接查看。</p>
<h2>分析师评级变动</h2>
<p>几位股票分析师最近对该股票发表了评论。Weiss Ratings 在 9 月 27 日星期六的研究报告中重申了对 GRAIL 股票的 “卖出（d-）” 评级。Canaccord Genuity Group 将 GRAIL 股票的目标价从 43.00 美元上调至 75.00 美元，并在周五的研究报告中给予该股票 “买入” 评级。最后，瑞银集团在周五的研究报告中设定了 GRAIL 股票的 75.00 美元目标价。一位投资分析师给予该股票 “买入” 评级，三位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 56.67 美元。</p>
<ul>
<li>GRAIL：瞄准 1000 亿美元癌症市场的生物科技股票</li>
</ul>
<p><strong>阅读我们对 GRAIL 的最新股票分析</strong></p>
<h2>GRAIL 股价下跌 3.5%</h2>
<p>该公司的 50 日移动平均线为 38.69 美元，200 日移动平均线为 37.25 美元。该公司的市值为 22.8 亿美元，市盈率为-4.82，贝塔值为 4.11。</p>
<ul>
<li>战略性买入点燃这只生物科技股票：是时候投资了吗？</li>
</ul>
<p>GRAIL（纳斯达克代码：GRAL - 获取免费报告）最近一次发布季度财报是在 8 月 12 日星期二。该公司报告每股收益（EPS）为-3.18 美元，低于市场共识预期的-3.14 美元，差距为 0.04 美元。GRAIL 的净利润率为-329.86%，股本回报率为-16.64%。该公司在本季度的收入为 3,554 万美元，而分析师预期为 3,757 万美元。分析师预测 GRAIL, Inc.在当前财年将发布-15.15 的每股收益。</p>
<h2>GRAIL 的机构交易</h2>
<p>对冲基金最近买入和卖出了该公司的股票。Caldwell Sutter Capital Inc.在第一季度新建了 28,000 美元的 GRAIL 头寸。KBC Group NV 在第一季度将其在 GRAIL 的持股增加了 187.7%。KBC Group NV 目前持有 1,430 股公司股票，价值 37,000 美元，此前在上个季度增持了 933 股。S.A. Mason LLC 在第一季度将其在 GRAIL 的持股增加了 50.1%。S.A. Mason LLC 目前持有 1,499 股公司股票，价值 38,000 美元，此前在上个季度增持了 500 股。Farther Finance Advisors LLC 在第二季度将其在 GRAIL 的持股增加了 768.1%。Farther Finance Advisors LLC 目前持有 816 股公司股票，价值 42,000 美元，此前在上个季度增持了 722 股。最后，NewEdge Advisors LLC 在第一季度将其在 GRAIL 的持股增加了 390.3%。NewEdge Advisors LLC 目前持有 1,760 股公司股票，价值 45,000 美元，此前在上个季度增持了 1,401 股。</p>
<h2>关于 GRAIL</h2>
<p>（获取免费报告）</p>
<p>GRAIL, Inc.是一家商业阶段的医疗保健公司，专注于开发早期癌症检测技术。它利用机器学习、软件和自动化技术在早期阶段检测和识别多种致命癌症类型。该公司由 Jeffrey T.创立。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 GRAIL 更具吸引力</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>进入假期前需要关注的 3 只旅游股票</li>
<li>3 只引领迷因股票复苏的股票</li>
<li>15 美元以下的最佳股票？3 只低价潜力股</li>
<li>如何开始投资于便士股票</li>
<li>D-Wave 的巨大一周背后（以及为什么竞争对手也上涨）</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 GRAIL 吗？</h2>
<p>在考虑 GRAIL 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 GRAIL 并不在名单上。</p>
<p>虽然 GRAIL 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>查看这五只股票</p>

GRAL

<p>GRAIL, Inc.（纳斯达克代码：GRAL）股价下跌 4%，原因是总裁 Joshua J. Ofman 出售了 9,692 股，售价为每股 64.00 美元。该股最低交易价为 60.02 美元，收盘价为 62.95 美元，交易量较平均水平下降了 61%。分析师的评级不一，包含一项买入、三项持有和一项卖出，目标价共识为 56.67 美元。GRAIL 报告季度每股亏损 3.18 美元，未达到预期，市值为 22.8 亿美元</p>

<p>GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) shares were down 4% on Monday after an insider sold shares in the company. The company traded as low as $60.02 and last traded at $62.95. Approximately 494,947 shares traded hands during trading, a decline of 61% from the average daily volume of 1,277,161 shares. The stock had previously closed at $65.55.</p>
<div class="lb-trans"><p>GRAIL, Inc.（纳斯达克代码：GRAL - 获取免费报告）周一股价下跌 4%，原因是公司内部人士出售了该公司的股票。该公司股价最低曾达到 60.02 美元，最后交易价格为 62.95 美元。在交易过程中，约有 494,947 股成交，较日均成交量 1,277,161 股下降了 61%。该股票此前收盘价为 65.55 美元。</p>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表现优于市场的 3 只医疗科技股票</li>
</ul>
</div><p>Specifically, President Joshua J. Ofman sold 9,692 shares of the company's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $64.00, for a total value of $620,288.00. Following the transaction, the president directly owned 478,182 shares in the company, valued at $30,603,648. The trade was a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink.</p>
<div class="lb-trans"><p>具体来说，首席执行官 Joshua J. Ofman 在 10 月 2 日星期四出售了 9,692 股公司的股票。股票的平均售价为 64.00 美元，总价值为 620,288.00 美元。交易后，首席执行官直接持有 478,182 股公司股票，价值 30,603,648 美元。这笔交易使其持股比例减少了 1.99%。该交易已在提交给证券交易委员会的文件中披露，相关文件可通过此链接查看。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several equities analysts recently commented on the stock. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of GRAIL in a research note on Saturday, September 27th. Canaccord Genuity Group increased their price objective on shares of GRAIL from $43.00 to $75.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday. Finally, UBS Group set a $75.00 price objective on shares of GRAIL in a research note on Friday. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and a consensus target price of $56.67.</p>
<div class="lb-trans"><p>几位股票分析师最近对该股票发表了评论。Weiss Ratings 在 9 月 27 日星期六的研究报告中重申了对 GRAIL 股票的 “卖出（d-）” 评级。Canaccord Genuity Group 将 GRAIL 股票的目标价从 43.00 美元上调至 75.00 美元，并在周五的研究报告中给予该股票 “买入” 评级。最后，瑞银集团在周五的研究报告中设定了 GRAIL 股票的 75.00 美元目标价。一位投资分析师给予该股票 “买入” 评级，三位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，共识目标价为 56.67 美元。</p>
</div><ul>
<li>GRAIL: Biotech Stock Targeting $100B Cancer Market</li>
</ul>
<div class="lb-trans"><ul>
<li>GRAIL：瞄准 1000 亿美元癌症市场的生物科技股票</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on GRAIL</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 GRAIL 的最新股票分析</strong></p>
</div><h2>GRAIL Trading Down 3.5%</h2>
<div class="lb-trans"><h2>GRAIL 股价下跌 3.5%</h2>
</div><p>The firm's 50-day moving average is $38.69 and its 200-day moving average is $37.25. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -4.82 and a beta of 4.11.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 38.69 美元，200 日移动平均线为 37.25 美元。该公司的市值为 22.8 亿美元，市盈率为-4.82，贝塔值为 4.11。</p>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>战略性买入点燃这只生物科技股票：是时候投资了吗？</li>
</ul>
</div><p>GRAIL (NASDAQ:GRAL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.14) by ($0.04). GRAIL had a negative net margin of 329.86% and a negative return on equity of 16.64%. The business had revenue of $35.54 million during the quarter, compared to analyst estimates of $37.57 million. Analysts forecast that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>GRAIL（纳斯达克代码：GRAL - 获取免费报告）最近一次发布季度财报是在 8 月 12 日星期二。该公司报告每股收益（EPS）为-3.18 美元，低于市场共识预期的-3.14 美元，差距为 0.04 美元。GRAIL 的净利润率为-329.86%，股本回报率为-16.64%。该公司在本季度的收入为 3,554 万美元，而分析师预期为 3,757 万美元。分析师预测 GRAIL, Inc.在当前财年将发布-15.15 的每股收益。</p>
</div><h2>Institutional Trading of GRAIL</h2>
<div class="lb-trans"><h2>GRAIL 的机构交易</h2>
</div><p>Hedge funds have recently bought and sold shares of the business. Caldwell Sutter Capital Inc. bought a new position in GRAIL during the 1st quarter valued at $28,000. KBC Group NV lifted its stake in GRAIL by 187.7% during the 1st quarter. KBC Group NV now owns 1,430 shares of the company's stock valued at $37,000 after acquiring an additional 933 shares in the last quarter. S.A. Mason LLC lifted its stake in GRAIL by 50.1% during the 1st quarter. S.A. Mason LLC now owns 1,499 shares of the company's stock valued at $38,000 after acquiring an additional 500 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in GRAIL by 768.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 816 shares of the company's stock valued at $42,000 after acquiring an additional 722 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock valued at $45,000 after acquiring an additional 1,401 shares in the last quarter.</p>
<div class="lb-trans"><p>对冲基金最近买入和卖出了该公司的股票。Caldwell Sutter Capital Inc.在第一季度新建了 28,000 美元的 GRAIL 头寸。KBC Group NV 在第一季度将其在 GRAIL 的持股增加了 187.7%。KBC Group NV 目前持有 1,430 股公司股票，价值 37,000 美元，此前在上个季度增持了 933 股。S.A. Mason LLC 在第一季度将其在 GRAIL 的持股增加了 50.1%。S.A. Mason LLC 目前持有 1,499 股公司股票，价值 38,000 美元，此前在上个季度增持了 500 股。Farther Finance Advisors LLC 在第二季度将其在 GRAIL 的持股增加了 768.1%。Farther Finance Advisors LLC 目前持有 816 股公司股票，价值 42,000 美元，此前在上个季度增持了 722 股。最后，NewEdge Advisors LLC 在第一季度将其在 GRAIL 的持股增加了 390.3%。NewEdge Advisors LLC 目前持有 1,760 股公司股票，价值 45,000 美元，此前在上个季度增持了 1,401 股。</p>
</div><h2>About GRAIL</h2>
<div class="lb-trans"><h2>关于 GRAIL</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.</p>
<div class="lb-trans"><p>GRAIL, Inc.是一家商业阶段的医疗保健公司，专注于开发早期癌症检测技术。它利用机器学习、软件和自动化技术在早期阶段检测和识别多种致命癌症类型。该公司由 Jeffrey T.创立。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than GRAIL</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>3 Travel Stocks to Watch Heading Into the Holidays</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Best Stocks Under $15? 3 Low-Priced Picks With Upside</li>
<li>How to start investing in penny stocks</li>
<li>Behind D-Wave's Massive Week (And Why Rivals Also Popped)</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 GRAIL 更具吸引力</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>进入假期前需要关注的 3 只旅游股票</li>
<li>3 只引领迷因股票复苏的股票</li>
<li>15 美元以下的最佳股票？3 只低价潜力股</li>
<li>如何开始投资于便士股票</li>
<li>D-Wave 的巨大一周背后（以及为什么竞争对手也上涨）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GRAIL Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 GRAIL 吗？</h2>
</div><p>Before you consider GRAIL, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 GRAIL 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 GRAIL 并不在名单上。</p>
</div><p>While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 GRAIL 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

GRAIL（纳斯达克股票代码：GRAL）在内部人士出售股票后股价下跌 4%